ORPHA:402823
Hepatitis delta
Also known as: HDV · Hepatitis D virus
Publications
15,333
96.3th percentile
Trials
51
Interventional, condition-specific
Researchers
1,692
Distinct authors in sample
Gene link
—
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
Hepatitis delta is a rare hepatic disease characterized by variable degrees of acute hepatitis resulting from infection with the hepatitis delta virus. Occasionally it may present a benign course, but most frequently it manifests with severe liver disease that may include fulminant liver failure, hepatic decompensation and rapid progression to cirrhosis. All patients present concomitant hepatitis B virus infection and an increased risk of developing hepatocellular carcinoma has been reported.
How rare: 1-5 / 10 000 — about one to five people per ten thousand (still uncommon, but less ultra-rare).
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0005789
- MeSH:D003699
- UMLS:C0011226
Additional Mondo synonyms (5)
Hepatitis D · Hepatitis delta virus caused hepatitis · Hepatitis delta virus hepatitis · hepatitis delta · hepatitis type D
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
15,333 matched papers (7,651 in last 10 years) Source
- Phenotype characterisedPresent
19 HPO annotations (e.g. Cirrhosis; Abdominal pain; Anorexia) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
51 matched on ClinicalTrials.gov (8 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
19
Associated phenotypes · MONDO:0005789
- Cirrhosis
- Abdominal pain
- Anorexia
- Poor appetite
- Fulminant hepatitis
Showing 5 of 19 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
21
Drugs / clinical candidates · MONDO_0005789
- ELEBSIRAN·phase 3
- HEPALATIDE·phase 3
- INTERFERON ALFA-2A·phase 3
- LONAFARNIB·phase 3
- PEGINTERFERON ALFA-2A·phase 3
- PEGINTERFERON ALFA-2B·phase 3
- RITONAVIR·phase 3
- TENOFOVIR ANHYDROUS·phase 3
- TOBEVIBART·phase 3
- ENTECAVIR·phase 2
- EZETIMIBE·phase 2
- INTERFERON ALFA·phase 2
- LIBEVITUG·phase 2
- PEGINTERFERON LAMBDA-1A·phase 2
- RIBAVIRIN·phase 2
CTD chemicals (MyDisease.info)
1 associated chemical. Therapeutic evidence is listed first when present — not a treatment recommendation.
- Hepatitis B Surface Antigens · marker/mechanism
Literature
Is anyone studying this?
15,333
15,333 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
15,333 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
7,651 in the last 10 years · medium confidence · 96.3th percentile (publications denominator)
Phrase hits: 15,333 · MeSH hits: 275
Who's working on it?
1,692
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Lampertico P17 papers · 2026
Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Papers in Europe PMC - 02Wedemeyer H13 papers · 2026
D-SOLVE consortium, an EU Horizon Europe funded project (No 101057917), Hannover, Germany.
Papers in Europe PMC - 03Buti M10 papers · 2026
Liver Unit, Hospital Univesitari Vall d'Hebron, Barcelona, Spain.
Papers in Europe PMC - 04Aleman S7 papers · 2026
Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.
Papers in Europe PMC - 05Zoulim F7 papers · 2026
INSERM Unité Mixte de Recherche 1350, PaThLiv IHU EVEREST, Université Claude-Bernard Lyon 1, 69003 Lyon, France; (A.A.R.S.); (E.B.); (F.Z.); (B.T.); (I.C.)
Papers in Europe PMC - 06Casado M6 papers · 2026
Pharmacoeconomics & Outcomes Research Iberia (PORIB), Madrid, Spain.
Papers in Europe PMC - 07Degasperi E6 papers · 2026
Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Papers in Europe PMC - 08García F6 papers · 2026
Hospital Universitario Clínico San Cecilio, Granada, Spain.
Papers in Europe PMC - 09Sandmann L6 papers · 2026
Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany.
Papers in Europe PMC - 10Agarwal K5 papers · 2026
Institute of Liver Studies, King's College Hospital London, United Kingdom.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
51
interventional trials for this specific condition
51 interventional trials matched this specific condition name; 8 currently recruiting in our sample. 3,367 trials are registered for hepatitis, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026
51 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 97.2th percentile).
medium confidence · 97.2th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
51 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT07200908·RECRUITING·A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)
Not reviewed·Conditions: Chronic Hepatitis D Infection·Matched via name + MeSH
- NCT07610772·RECRUITING·Safety and Antiviral Activity of a Monoclonal Hepatitis B Antibody: a Phase 1b, Open-label Trial in Individuals With Chronic Hepatitis D Infection
Not reviewed·Conditions: Hepatitis D, Chronic · Hepatitis B Chronic Infection·Matched via name + MeSH
- NCT07038863·NOT YET RECRUITING·Community Screening and Management of Hepatitis B, C and Delta in the Mongolian Population Living in France
Not reviewed·Conditions: HEPATITIS C (HCV) · Hepatitis B Virus (HBV) · Hepatitis D · Hepatocellular Carcinoma (HCC)·Matched via name + MeSH
- NCT07454837·RECRUITING·Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide
Not reviewed·Conditions: Chronic Hepatitis D·Matched via name + MeSH
- NCT06649396·NOT YET RECRUITING·Determination of New Detection and Quantification Thresholds for Serological and Molecular Tests for Hepatitis Delta Virus (HDV) Using Capillary Blood on Blotting Paper (DBS)
Not reviewed·Conditions: Delta Hepatitis·Matched via name phrase
- NCT07499544·RECRUITING·A Phase III Study to Evaluate the Efficacy and Safety of Libevitug in Participants With Chronic HDV Infection (D-clear Study)
Not reviewed·Conditions: Chronic Hepatitis D Infection·Matched via name + MeSH
- NCT07096193·RECRUITING·Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta Virus
Not reviewed·Conditions: Chronic Hepatitis Delta·Matched via name phrase
- NCT07309380·NOT YET RECRUITING·Phase III Clinical Trial of Hepalatide in Patients With Chronic Hepatitis D
Not reviewed·Conditions: Hepatitis D, Chronic·Matched via name + MeSH
Broader category: hepatitis
3,367
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT06484530·RECRUITING·Gene-guided N-acetyl Cysteine for Prophylaxis of Anti-tuberculous Drug- Induced Hepatitis
Not reviewed·Conditions: Tuberculosis (TB) · Isoniazid Toxicity · Rifampicin Toxicity · Pyrazinamide Adverse Reaction·Matched via name phrase
- NCT06381453·RECRUITING·Belimumab in Autoimmune Hepatitis
Not reviewed·Conditions: Autoimmune Hepatitis·Matched via name phrase
- NCT07589400·NOT YET RECRUITING·Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of ACT500 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Complicated With Chronic Hepatitis B
Not reviewed·Conditions: Metabolic Dysfunction-associated Steatotic Liver Disease · Chronic Hepatitis b·Matched via name phrase
- NCT05304234·RECRUITING·Liver Cancer Disparities in American Indian and Alaska Native Persons
Not reviewed·Conditions: Hepatocellular Carcinoma · Cirrhosis, Liver · Hepatitis B·Matched via name phrase
- NCT05182463·RECRUITING·Peginterferon Treatment Study for Inactive Chronic Hepatitis B Patients
Not reviewed·Conditions: Hepatitis B, Chronic·Matched via name phrase
- NCT07137910·RECRUITING·A Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB)
Not reviewed·Conditions: Chronic Hepatitis B·Matched via name phrase
- NCT05769816·RECRUITING·A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (A)
Not reviewed·Conditions: Chronic Hepatitis b · Anti-PD-1 Antibody·Matched via name phrase
- NCT07145268·NOT YET RECRUITING·Zinc Sulphate in Treatment Fibrosis in HBV Patient Receiving Antiviral Therapy
Not reviewed·Conditions: Liver Fibroses · HBV (Hepatitis B Virus)·Matched via name phrase
- NCT06956482·RECRUITING·PROlonged Corticosteroid Treatment or N-ACetylcysteine for Severe Alcoholic Hepatitis
Not reviewed·Conditions: Alcoholic Hepatitis·Matched via name phrase
- NCT07253220·NOT YET RECRUITING·TAF Monotherapy Versus ETV Combined With TAF on the Efficacy and Prognosis of Immunotherapy for Hepatitis B-Related Hepatocellular Carcinoma
Not reviewed·Conditions: Hepatitis B · Hepatocellular Carcinoma (HCC)·Matched via name phrase
- NCT07024641·RECRUITING·A Study to Assess the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 in Participants With Chronic Hepatitis B Virus Infection
Not reviewed·Conditions: Hepatitis B Virus Infection·Matched via name phrase
- NCT07017426·NOT YET RECRUITING·Fuzheng Huayu Tablets Reduce the Occurrence of Re-Decompensation Events in Patients With First Decompensation of Hepatitis B-Related Liver Cirrhosis: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study
Not reviewed·Conditions: Decompensated Hepatitis B Cirrhosis·Matched via name phrase
- NCT06323681·RECRUITING·Pegylated Interferon α in Previously Interferon-treated CHB(Leading Study)
Not reviewed·Conditions: Chronic Hepatitis b·Matched via name phrase
- NCT07342881·RECRUITING·Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function
Not reviewed·Conditions: Chronic Hepatitis B Infection·Matched via name phrase
- NCT04357600·ENROLLING BY INVITATION·Umbilical Cord Mesenchymal Stem Cell for Liver Cirrhosis Patient Caused by Hepatitis B
Not reviewed·Conditions: Liver Cirrhoses·Matched via name phrase
Observational and natural-history studies
43 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT06397859·RECRUITING·Effectiveness and Clinical Outcomes of Long-term Bulevirtide Monotherapy in Patients With HDV-related Compensated Cirrhosis
Not reviewed·Conditions: Hepatitis D·Matched via name + MeSH
- NCT06248580·RECRUITING·Find HDV and Determine Its Status in Turkey
Not reviewed·Conditions: Chronic Hepatitis D Infection · Fibrosis, Liver · Hepatocellular Carcinoma · Cirrhosis, Liver·Matched via name + MeSH
- NCT05451082·NOT YET RECRUITING·Registry-based Study in Patients With Hepatitis D Virus (HDV) Infection in China
Not reviewed·Conditions: Hepatitis D·Matched via name + MeSH
- NCT06504485·RECRUITING·Immunological and Virological Characterization of Patients With Chronic HBV-HDV Infection: Outcomes and Response to Bulevirtide Treatment
Not reviewed·Conditions: Hepatitis D·Matched via name + MeSH
- NCT07491848·RECRUITING·Oral-Periodontal Evaluation and Assessment of Oral Fluid Biomarkers in Patients With Hepatitis B+D
Not reviewed·Conditions: HEPATITIS B CHRONIC · Hepatitis D · Periodontitis·Matched via name + MeSH
- NCT07317011·RECRUITING·"Referral Attivo" Delta, Dallo Screening Alla Presa in Carico.
Not reviewed·Conditions: Hepatitis, Delta·Matched via name phrase
- NCT04690972·RECRUITING·"Constitution of a Biological Collection to Establish Preclinical Translational Models for the Study of Tumors and Chronic Liver Diseases".
Not reviewed·Conditions: Chronic Liver Disease and Cirrhosis · Liver Cancer · Non-Alcoholic Fatty Liver Disease · Non-Alcoholic Steatohepatitis·Matched via name + MeSH
- NCT04166266·RECRUITING·National Cohort of Patients Co-infected With Hepatitis B and Delta Viruses
Not reviewed·Conditions: Hepatitis D, Chronic · Hepatitis B, Chronic·Matched via name + MeSH
- NCT06638320·RECRUITING·Hepatitis Delta Virus Infection: Cross-sectional Study in Patients With Chronic Hepatitis B Virus Infection
Not reviewed·Conditions: Hepatitis Delta With Hepatitis B Carrier State · Chronic Hepatitis b·Matched via name phrase
- NCT00001971·RECRUITING·Evaluation of Patients With Liver Disease
Not reviewed·Conditions: Hepatitis D · Hepatitis C · Hepatitis B · Liver Disease·Matched via name + MeSH
- NCT06889805·RECRUITING·HDV Screening Study
Not reviewed·Conditions: Hepatitis D Virus Infection·Matched via name + MeSH
- NCT06122285·RECRUITING·Effectiveness and Safety of Bulevirtide (BLV) Therapy in Patients With Chronic Hepatitis Delta (CHD) in Italy (D-SHIELD)
Not reviewed·Conditions: Hepatitis D·Matched via name + MeSH
- NCT06051045·RECRUITING·Study to Evaluate Efficacy, Safety and Biomarkers of Bulevirtide Treatment in Chronic Hepatitis D Patients
Not reviewed·Conditions: Chronic Hepatitis D·Matched via name + MeSH
- NCT05936073·RECRUITING·DELTA DESCRIBE: the French Collaborative Project
Not reviewed·Conditions: Hepatitis D·Matched via name + MeSH
- NCT06539052·NOT YET RECRUITING·MIGrant Reflex Test HDV (MIGRED) Project
Not reviewed·Conditions: Hepatitis D Virus Infection·Matched via name + MeSH
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 80 · after dedupe 78 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 78 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (78)
- ctis·2025-522729-36-00·Authorised, recruiting·Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta.
skipped — LLM skipped (--skip-llm)
- ctis·2025-522015-42-00·Authorised, ongoing·A Phase 2b/3, Open-Label, Multicenter Trial Evaluating the Efficacy and Safety of Switching to Brelovitug for the Treatment of Chronic Hepatitis Delta Infection in Participants Receiving Bulevirtide (AZURE-3)
skipped — LLM skipped (--skip-llm)
- ctis·2025-522105-38-00·Expired·A Randomized, Open-label, Multicenter, Phase 3 Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)
skipped — LLM skipped (--skip-llm)
- ctis·2024-517167-23-00·Authorised, ongoing·A Global, Randomized, Open-label, Multicenter Phase 3 Trial Evaluating BJT-778 vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)
skipped — LLM skipped (--skip-llm)
- ctis·2024-519063-18-00·Expired·A Global, Randomized, Open-label, Multicenter, Phase 2b/3 Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-1)
skipped — LLM skipped (--skip-llm)
- ctis·2024-520062-54-00·Expired·A Phase 2b Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Tobevibart+Elebsiran Combination Therapy versus Bulevirtide in Participants with Chronic HDV Infection (ECLIPSE 3)
skipped — LLM skipped (--skip-llm)
- ctis·2024-512203-40-00·Expired·A Phase 2 Study to Evaluate Efficacy, Safety and Tolerability of VIR-2218 and VIR-3434 in Participants with Chronic Hepatitis D Virus Infection (SOLSTICE)
skipped — LLM skipped (--skip-llm)
- ctis·2022-502724-46-00·Suspended·A Phase 1/2a, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of BJT-778 in Healthy Volunteers and in Subjects with Chronic Hepatitis B Infection, Including Subjects with Chronic Hepatitis D Infection
skipped — LLM skipped (--skip-llm)
- ctis·2023-509007-33-00·Expired·A phase 2a, multicentre trial to evaluate the efficacy, safety and pharmacokinetics of RBD1016 in participants with chronic hepatitis D virus infection, including a randomized, single-blinded, placebo-controlled exploratory part
skipped — LLM skipped (--skip-llm)
- ctis·2023-506763-33-00·Cancelled·A Phase 2, Multicenter, Randomized, Double-blind, Placebo‑controlled Study with Deferred Active Treatment to Investigate the Efficacy, Safety, and Pharmacokinetics of JNJ‑73763989 + Nucleos(t)ide Analog in Participants Co‑infected with Hepatitis B and Hepatitis D Virus
skipped — LLM skipped (--skip-llm)
- ctis·2025-522125-36-00·Authorised, recruiting·A study to determine the safety and effect of antibodies against hepatitis D (the SAMBA-D study)
skipped — LLM skipped (--skip-llm)
- ctis·2023-504414-29-00·Authorised, ongoing·Observational Study to Evaluate Efficacy, Safety and Biomarkers of Bulevirtide Treatment in Patients with Chronic hepatitis D
skipped — LLM skipped (--skip-llm)
- ctis·2022-501901-10-00·Cancelled·A Registry Study of Treatment With Bulevirtide in Participants With Chronic Hepatitis D Infection
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN30672343·No longer recruiting·A study to investigate the effects of two painkillers as a combination treatment for pain
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN44123892·No longer recruiting·A 24-week trial to compare the efficacy and safety of delgocitinib cream 20 mg/g twice-daily with alitretinoin capsules once daily in adult participants with severe chronic hand eczema
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN18402242·No longer recruiting·A trial to investigate whether a new medicine, KAND567, is well tolerated and if it can improve healing in patients who have had a heart attack
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN41927312·No longer recruiting·Adhesion study of Flectoparin® Tissugel following plaster application
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN36524222·Stopped·Are inorganic nitrates protective for fatty liver?
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN83445469·No longer recruiting·A Clinical Trial Evaluating a Total Disc Replacement in Patients with Cervical Disc Disease
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN67182335·No longer recruiting·Effect of an enteral diet enriched with gamma linolenic acid, eicosapentaenoic acid and antioxidants upon the course of critically ill patients with sepsis
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN91288089·No longer recruiting·Repeated autologous infusions of stem cells in cirrhosis
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN85175364·No longer recruiting·LEVOsimendan before Heart-Lung-Machine in coronary artery bypass graft operations
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN77940178·No longer recruiting·Clinical trial of sustained release methylphenidate for Attention Deficit Hyperactivity Disorder (ADHD) in adult criminal offenders with amphetamine addiction
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN83069092·No longer recruiting·Dutch Evaluation in Liver Transplantation To Assess the efficacy of Neoral® (cyclosporin A) with C-2h monitoring versus Prograft® (tacrolimus) with trough monitoring in de novo liver transplant recipients
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN52111708·No longer recruiting·Hepatitis B immunoglobulin (HBIg) withdrawal from combination lamivudine (LAM)/HBIg prophylaxis in liver transplant recipients
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Hepatitis delta — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Hepatitis delta" OR "Hepatitis D virus" OR "Hepatitis D" OR "Hepatitis delta virus caused hepatitis" OR "Hepatitis delta virus hepatitis" OR "hepatitis type D"
MeSH descriptor terms unioned into the query: Hepatitis D
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Hepatitis delta" OR "Hepatitis D virus" OR "Hepatitis D" OR "Hepatitis delta virus caused hepatitis" OR "Hepatitis delta virus hepatitis" OR "hepatitis type D"
Interventional trials matched via: both, phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 51 interventional · 43 observational · 2 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"hepatitis"
Query health: ok — strategies attempted: phrase, mesh; with hits: phrase, mesh
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: HDV
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T15:33:02.877Z
